BioMedNewsBreaks

FridayNov 13, 2026 11:00 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports $12.22 Million in Cash and Digital Assets, Advances Lucid-MS Phase 2 Trial

Quantum BioPharma (NASDAQ: QNTM) reported unaudited financial and operational results for the third quarter ended Sept. 30, 2026, highlighting improved liquidity, reduced operating expenses and progress in its clinical development program. Cash and cash equivalents totaled approximately $3.56 million, while digital assets reached $8.66 million, representing combined holdings of $12.22 million, compared with $4.12 million at year-end 2025, excluding restricted digital assets. Shareholders' equity increased 91% to $9.77 million, while working capital rose to $5.47 million from $420,000. Third-quarter operating expenses declined 24% year over year to $3.56 million, and the nine-month net loss narrowed 26% to $17.32 million from…

Continue Reading

ThursdayNov 12, 2026 1:37 pm

BioMedNewsBreaks – Earth Science Tech Inc. (ETST) Leverages Vertically Integrated Business Model to Drive Growth and Profitability

Earth Science Tech (OTCQB: ETST) is leveraging its diversified conglomerate business model to build a vertically integrated healthcare platform while expanding its presence across real estate, asset management and consumer products. Its healthcare operations combine compounding pharmacies, telemedicine, clinical support and direct-to-patient fulfillment, supported by internal technology, proprietary physician networks and owned real estate. The company’s acquisition of Zoolzy LLC, a wholesale distributor of active pharmaceutical ingredients and FDA-approved prescription products, further strengthens supply chain control and provides its pharmacies with access to competitively priced ingredients. By bringing more operational functions in-house and leveraging the capabilities of its subsidiaries, Earth…

Continue Reading

ThursdayNov 12, 2026 1:08 pm

BioMedNewsBreaks – Adaptogenics Health Corp. (CSE: ADPT) Positions for Emerging Peptide Market with Focus on Quality, Traceability

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT) is positioning itself to address growing demand for quality assurance and transparency in the emerging regulated peptide market through a strategy focused on dependable supply, documented traceability, independent third-party verification and science-based product development. As U.S. regulators consider expanding access to certain compounded peptides while raising concerns about product purity, impurities and safety, the company plans to establish a U.S.-based, GMP-standard supply network using qualified manufacturers and independent laboratories to verify peptide identity and quality. Led by CEO Dr. J. David Warren, a medicinal and…

Continue Reading

WednesdayNov 11, 2026 9:10 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports Shareholder Meeting Results, Closes Private Placement Increasing Insider Voting Control

Quantum BioPharma (NASDAQ: QNTM) announced the results of its Nov. 10, 2026, annual general and special meeting of shareholders and the closing of a non-brokered private placement of 26 Class A multiple voting shares on Nov. 9. Shareholders elected all five director nominees, reappointed MNP LLP as auditor and approved several resolutions, including authorization to issue additional Class A multiple voting shares to maintain up to 70% aggregate voting power, a 2026 omnibus equity incentive plan, a potential share consolidation at a ratio of up to 10-for-1 and a potential corporate name change. The board retains discretion over implementing the…

Continue Reading

TuesdayNov 10, 2026 10:10 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Publishes Phase 1a Glioblastoma Data, Advances LP-184 Combination Therapy Toward Phase 1b/2a Trial

Lantern Pharma (NASDAQ: LTRN) and its wholly owned subsidiary, Starlight Therapeutics, announced the publication of Phase 1a clinical data for LP-184 (zirdafulven), also being developed as STAR-001, in patients with recurrent glioblastoma ("GBM"). Published in the October 2026 issue of Cancer Research Communications, the study evaluated 16 patients and found LP-184 was generally well tolerated, establishing a recommended expansion dose of 0.39 mg/kg. No objective radiographic responses were observed, although one patient remained clinically and radiographically stable for more than 22 months after enrollment. The findings also identified limited drug exposure in brain tumors, supporting further evaluation of LP-184 in…

Continue Reading

MondayNov 09, 2026 12:19 pm

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Signs Four-Year Exclusive Distribution Agreement for GelrinC (R) in Israel

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, announced a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. for the commercialization of GelrinC (R), its proprietary implant for repairing damaged knee cartilage, in Israel. GelrinC has received regulatory approval from Israel's Ministry of Health for the same indication approved in Europe and being pursued in the United States. Under the agreement, AMI will leverage its established relationships with orthopedic surgeons, hospitals and clinics to support the product's commercial introduction. The agreement includes minimum purchase requirements, with Regentis expecting initial revenue contributions beginning in…

Continue Reading

FridayNov 06, 2026 10:09 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Files Supplement to Shareholder Meeting Materials Clarifying Share Consolidation Terms

Quantum BioPharma (NASDAQ: QNTM) announced that it has filed a supplement to its Sept. 28, 2026, management information circular ahead of its annual general and special meeting of shareholders scheduled for Nov. 10, 2026. The supplement corrects and restates the proposed special resolution authorizing a consolidation of the company's Class A multiple voting shares and Class B subordinate voting shares. Under the clarified terms, fractional shares equal to or less than one-half will be rounded down to the nearest whole share, while fractions greater than one-half will be rounded up. The company also clarified that it will implement measures to…

Continue Reading

ThursdayNov 05, 2026 2:43 pm

BioMedNewsBreaks – Earth Science Tech Inc. (ETST) Builds Long-Term Value Through Strategic Integration

Earth Science Tech (OTCQB: ETST), a diversified holding company operating across healthcare, pharmacy, technology, telemedicine, real estate, and consumer products, is leveraging synergies among its subsidiaries to support long-term growth and generate dependable revenue. Its real estate and asset management subsidiary, Avenvi LLC, contributes to this strategy through its diversified real estate portfolio, property development expertise, and financing solutions for property purchasers. In addition to managing investments and overseeing ETST’s share repurchase program, Avenvi provides essential physical infrastructure for the company’s expanding pharmacy operations, including housing the standalone Mister Meds compounding pharmacy in Texas. Through its real estate capabilities, disciplined…

Continue Reading

ThursdayNov 05, 2026 2:06 pm

BioMedNewsBreaks – Why Adaptogenics Health Corp. (CSE: ADPT) Is ‘One to Watch’

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT) was featured in a recent article that discussed its efforts to build a healthcare company focused on opportunities across the rapidly evolving peptide sector, combining proprietary therapeutic development, pharmaceutical-quality supply infrastructure and innovative drug delivery technologies. “As demand for solutions addressing metabolic health, muscle preservation, recovery and healthy ageing continues to grow, Adaptogenics is positioning itself to address significant healthcare challenges while pursuing opportunities in the expanding market for high-quality peptide development and supply,” the article reads. “The company’s strategy combines experienced pharmaceutical leadership, scientific…

Continue Reading

FridayOct 30, 2026 1:59 pm

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands NAMs Strategy to Advance BiTAC(R) Therapies

VERAXA Biotech (NASDAQ: VRXA) is expanding its use of human-relevant preclinical testing methods across its antibody-based cancer drug development programs, aiming to improve the clinical relevance of research findings while reducing animal testing. The company is implementing New Approach Methodologies (“NAMs”), including three-dimensional tumor spheroid models and patient-derived tumor models, in support of its BiTAC(R) T-cell engagers, antibody-drug conjugates and bispecific antibody-drug conjugates. VERAXA reported that its lead BiTAC T-cell engager demonstrated selective, potent T-cell-mediated tumor-cell killing across 10 patient-derived non-small cell lung cancer models, while relevant controls showed minimal activity. The ex vivo study required approximately 10 mice, compared…

Continue Reading